Your browser doesn't support javascript.
loading
Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug.
Hussain, Zahir; Zhu, Junjie; Ma, Xiaochao.
Affiliation
  • Hussain Z; Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Zhu J; Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Ma X; Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, Pennsylvania mxiaocha@pitt.edu.
Drug Metab Dispos ; 49(8): 679-682, 2021 08.
Article in En | MEDLINE | ID: mdl-34074731
ABSTRACT
Pyrazinamide (PZA) is an important component of a standard combination therapy against tuberculosis. However, PZA is hepatotoxic, and the underlying mechanisms are poorly understood. Biotransformation of PZA in the liver was primarily suggested behind its hepatoxicity. This review summarizes the knowledge of the key enzymes involved in PZA metabolism and discusses their contributions to PZA hepatotoxicity. SIGNIFICANCE STATEMENT This review outlines the current understanding of PZA metabolism and hepatotoxicity. This work also highlights the gaps in this field, which can be used to guide the future studies on PZA-induced liver injury.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazinamide / Tuberculosis / Chemical and Drug Induced Liver Injury / Liver Limits: Humans Language: En Journal: Drug Metab Dispos Journal subject: FARMACOLOGIA Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazinamide / Tuberculosis / Chemical and Drug Induced Liver Injury / Liver Limits: Humans Language: En Journal: Drug Metab Dispos Journal subject: FARMACOLOGIA Year: 2021 Document type: Article